Drug costs

Patients With DME Who Switched to Eylea Had Better Vision After a Year

August 17, 2020

Real-world evidence from 67 patients recently found benefits for those with diabetic macular edema who switched to Eylea from Lucentis.

Real-World Data: Psoriatic Arthritis Patients Stay on Cosentyx After Other Options Fail

August 10, 2020

A recent study found 64% of patients with psoriatic arthritis who had tried at least one biologic stayed with Cosentyx for the entire study period.

FDA Updates: Assays Used in Cancer Care Get Green Light

August 09, 2020

Adaptive Biotechnologies’ clonoSEQ gets third approval; FDA also acts on first at-home treatment for spinal muscular atrophy.

Jack Linehan of Epstein Becker Green Discusses Drug Coupons, Accumulators

July 09, 2020

In this week's episode of Tuning Into The C-Suite podcast, Senior Editor Peter Wehrwein has a conversation with John "Jack" Linehan, a lawyer for Epstein Becker Green, about coupons and accumulators. Jack is an expert on drug distribution and reimbursement, and few people know as much about coupons and accumulators as he does. Peter and Jack go over some of the basics, who is advantaged and disadvantaged, and then dive into some the details on CMS regulations and how recent proposed changes to Medicaid best price rules would, if finalized, affect coupons and accumulators.

Another Consequence of COVID-19: A Worsening of Drug Shortages

June 24, 2020

Demand for medications needed for patients who were intubated or put on a ventilator led to some shortages. The CARES Act has some provisions that may help deal with long-standing causes of the drug shortages that plague U.S. healthcare.

Express Scripts Report: Top Drug Classes Driving Spending Growth

February 26, 2020

Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.

Diabetes Drug Costs Drive Non-Adherence

November 11, 2019

A survey of diabetes educators reveals challenges faced by patients with diabetes who can’t afford their drugs.

Top 10 Disruptive Trends to Watch For

October 07, 2019

Looking ahead, here are the things most likely to impact managed care.

What Are Authorized Generics?

October 04, 2019

Authorized generics have been gaining popularity with pharmaceutical manufacturers, but just how do they impact pharmacies?

Report Details Trends in Medicaid Fee-for-Service Pharmacy Programs

September 29, 2019

New report outlines innovative state strategies for managing high-cost Medicaid prescription drugs.

Manufacturer-PBM Collaboration

September 24, 2019

Finding solutions to deliver better outcomes for patients.

340B Program Helps Rural Hospitals Stay Afloat

June 23, 2019

How hospitals are using savings from the 340B program to support other programs.

How Hypertargeting Patient Communication Lowers Drug Costs

June 22, 2019

Why lowering drug costs can start with machine learning and better patient interaction.

How Payers Are Keeping Specialty Drug Costs Down

April 11, 2019

The real-world strategies used to manage the high cost of specialty meds.

The State of Drug Rebates

April 10, 2019

The Trump Administration has taken a large interest in PBM drug rebates, which they say create higher drug prices. But do they?

State Adopts “Netflix” Model to Pay for Hep C Drugs

January 30, 2019

Louisiana’s subscription model aims to rein in the hepatitis C epidemic in the state.

Midterm Election Results: 6 Ways Healthcare Could Change in 2019

December 06, 2018

Here’s how experts predict healthcare will unfold in 2019.

Top Barriers to Biosimilar Approval and Adoption in the U.S.

December 01, 2018

The biosimilar market is flourishing in Europe-why aren’t we seeing similar gains in the U.S.?

Four Biosimilar Growth Opportunities to Watch

November 13, 2018

The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.